{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:05:24Z","timestamp":1789992324784,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":84,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["No. 2024-MS-265"],"award-info":[{"award-number":["No. 2024-MS-265"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenyang Science and Technology Plan Project","award":["No. 21-173-9-7"],"award-info":[{"award-number":["No. 21-173-9-7"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"DOI":"10.1186\/s13062-026-00849-6","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:53:27Z","timestamp":1782759207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The PTHR1\/PKA\/CREB1 axis promotes osteosarcoma progression by activating the PVT1\/miR-590-3p\/AXIN2 ceRNA network to induce epithelial-mesenchymal transition"],"prefix":"10.1186","volume":"21","author":[{"given":"Jiaming","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weishang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"849_CR1","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/cancers14020360","volume":"14","author":"GA Odri","year":"2022","unstructured":"Odri GA, Tchicaya-Bouanga J, Yoon DJY, Modrowski D. Metastatic Progression of Osteosarcomas: A Review of Current Knowledge of Environmental versus Oncogenic Drivers. Cancers. 2022;14:360. https:\/\/doi.org\/10.3390\/cancers14020360.","journal-title":"Cancers"},{"key":"849_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.12.024","volume":"500","author":"C Chen","year":"2021","unstructured":"Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021;500:1\u201310. https:\/\/doi.org\/10.1016\/j.canlet.2020.12.024.","journal-title":"Cancer Lett"},{"key":"849_CR3","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/nejmra2103423","volume":"385","author":"PS Meltzer","year":"2021","unstructured":"Meltzer PS, Helman LJ. New Horizons in the Treatment of Osteosarcoma. N Engl J Med. 2021;385:2066\u201376. https:\/\/doi.org\/10.1056\/nejmra2103423.","journal-title":"N Engl J Med"},{"key":"849_CR4","doi-asserted-by":"publisher","first-page":"151654","DOI":"10.1016\/j.anndiagpath.2020.151654","volume":"49","author":"F Jafari","year":"2020","unstructured":"Jafari F, Javdansirat S, Sanaie S, Naseri A, Shamekh A, Rostamzadeh D, et al. Osteosarcoma: A comprehensive review of management and treatment strategies. Annals Diagn Pathol. 2020;49:151654. https:\/\/doi.org\/10.1016\/j.anndiagpath.2020.151654.","journal-title":"Annals Diagn Pathol"},{"key":"849_CR5","doi-asserted-by":"publisher","first-page":"6985","DOI":"10.3390\/ijms21196985","volume":"21","author":"C Yang","year":"2020","unstructured":"Yang C, Tian Y, Zhao F, Chen Z, Su P, Li Y, et al. Bone Microenvironment and Osteosarcoma Metastasis. Int J Mol Sci. 2020;21:6985. https:\/\/doi.org\/10.3390\/ijms21196985.","journal-title":"Int J Mol Sci"},{"key":"849_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3390\/diagnostics15050644","volume":"15","author":"A-V Patra\u0219cu","year":"2025","unstructured":"Patra\u0219cu A-V, \u021aarc\u0103 E, Lozneanu L, Ungureanu C, Moro\u0219an E, Parteni D-E, et al. The Role of Epithelial\u2013Mesenchymal Transition in Osteosarcoma Progression: From Biology to Therapy. Diagnostics. 2025;15:644. https:\/\/doi.org\/10.3390\/diagnostics15050644.","journal-title":"Diagnostics"},{"key":"849_CR7","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.3390\/cancers15205108","volume":"15","author":"BK Nirala","year":"2023","unstructured":"Nirala BK, Yamamichi T, Petrescu DI, Shafin TN, Yustein JT. Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis. Cancers. 2023;15:5108. https:\/\/doi.org\/10.3390\/cancers15205108.","journal-title":"Cancers"},{"key":"849_CR8","doi-asserted-by":"publisher","unstructured":"Wang S, Ren Q, Li G, Zhao X, Zhao X, Zhang Z. The targeted therapies for osteosarcoma via six major pathways. Curr Mol Pharmacol. 2023;17. https:\/\/doi.org\/10.2174\/1874467217666230821142839.","DOI":"10.2174\/1874467217666230821142839"},{"key":"849_CR9","doi-asserted-by":"publisher","unstructured":"Wang M, Li W, Han G, Bai X, Xie J. MicroRNA-605-3p Inhibited the growth and chemoresistance of osteosarcoma cells via negatively modulating RAF1. Protein Peptide Lett. 2024;31:559\u201368. https:\/\/doi.org\/10.2174\/0109298665314658240712051206.","DOI":"10.2174\/0109298665314658240712051206"},{"key":"849_CR10","doi-asserted-by":"publisher","unstructured":"Noda H, Okazaki M, Joyashiki E, Tamura T, Kawabe Y, Khatri A, et al. Optimization of PTH\/PTHrP hybrid peptides to derive a long-acting PTH analog (LA\u2010PTH). JBMR Plus. 2020;4. https:\/\/doi.org\/10.1002\/jbm4.10367.","DOI":"10.1002\/jbm4.10367"},{"key":"849_CR11","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.3390\/cancers15071982","volume":"15","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Su S, Li X. Parathyroid Hormone-Related Protein\/Parathyroid Hormone Receptor 1 Signaling in Cancer and Metastasis. Cancers. 2023;15:1982. https:\/\/doi.org\/10.3390\/cancers15071982.","journal-title":"Cancers"},{"key":"849_CR12","doi-asserted-by":"publisher","unstructured":"Edwards CM, Johnson RW. From Good to Bad: The opposing effects of pthrp on tumor growth, dormancy, and metastasis throughout cancer progression. Front Oncol. 2021;11. https:\/\/doi.org\/10.3389\/fonc.2021.644303.","DOI":"10.3389\/fonc.2021.644303"},{"key":"849_CR13","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1089\/dna.2019.4880","volume":"38","author":"S Li","year":"2019","unstructured":"Li S, Wu X, Pei Y, Wang W, Zheng K, Qiu E, et al. PTHR1 May Be Involved in Progression of Osteosarcoma by Regulating miR-124-3p-AR-Tgfb1i1, miR-27a-3p-PPARG-Abca1, and miR-103\/590-3p-AXIN2 Axes. DNA Cell Biol. 2019;38:1323\u201337. https:\/\/doi.org\/10.1089\/dna.2019.4880.","journal-title":"DNA Cell Biol"},{"key":"849_CR14","doi-asserted-by":"publisher","unstructured":"Walia MK, Taylor S, Ho PWM, Martin TJ, Walkley CR. Tolerance to sustained activation of the cAMP\/Creb pathway activity in osteoblastic cells is enabled by loss of p53. Cell Death & Disease. 2018;9. https:\/\/doi.org\/10.1038\/s41419-018-0944-8.","DOI":"10.1038\/s41419-018-0944-8."},{"key":"849_CR15","doi-asserted-by":"publisher","unstructured":"Al-Khan AA, Nimmo JS, Tayebi M, Ryan SD, Simcock JO, Tarzi R, et al. Parathyroid hormone receptor 1 (PTHR1) is a prognostic indicator in canine osteosarcoma. Sci Rep. 2020;10. https:\/\/doi.org\/10.1038\/s41598-020-58524-3.","DOI":"10.1038\/s41598-020-58524-3"},{"key":"849_CR16","doi-asserted-by":"publisher","first-page":"106418","DOI":"10.1016\/j.phrs.2022.106418","volume":"184","author":"M Hashemi","year":"2022","unstructured":"Hashemi M, Moosavi MS, Abed HM, Dehghani M, Aalipour M, Heydari EA, et al. Long non-coding RNA (lncRNA) H19 in human cancer: From proliferation and metastasis to therapy. Pharmacol Res. 2022;184:106418. https:\/\/doi.org\/10.1016\/j.phrs.2022.106418.","journal-title":"Pharmacol Res"},{"key":"849_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2174\/1381612826666200917150130","volume":"27","author":"Y Qi","year":"2021","unstructured":"Qi Y, Song C, Zhang J, Guo C, Yuan C. Oncogenic LncRNA CASC9 in Cancer Progression. Curr Pharm Design. 2021;27:575\u201382. https:\/\/doi.org\/10.2174\/1381612826666200917150130.","journal-title":"Curr Pharm Design"},{"key":"849_CR18","doi-asserted-by":"publisher","first-page":"154675","DOI":"10.1016\/j.prp.2023.154675","volume":"248","author":"KJ Baljon","year":"2023","unstructured":"Baljon KJ, Ramaiah P, Saleh EAM, Al-dolaimy F, Al-Dami FH, Gandla K, et al. LncRNA PVT1: as a therapeutic target for breast cancer. Pathol - Res Pract. 2023;248:154675. https:\/\/doi.org\/10.1016\/j.prp.2023.154675.","journal-title":"Pathol - Res Pract"},{"key":"849_CR19","doi-asserted-by":"publisher","first-page":"155019","DOI":"10.1016\/j.prp.2023.155019","volume":"253","author":"MA Hakami","year":"2024","unstructured":"Hakami MA, Hazazi A, Khan FR, Abdulaziz O, Alshaghdali K, Abalkhail A, et al. PVT1 lncRNA in lung cancer: A key player in tumorigenesis and therapeutic opportunities. Pathol - Res Pract. 2024;253:155019. https:\/\/doi.org\/10.1016\/j.prp.2023.155019.","journal-title":"Pathol - Res Pract"},{"key":"849_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2017.08.038","volume":"474","author":"D Lu","year":"2017","unstructured":"Lu D, Luo P, Wang Q, Ye Y, Wang B. lncRNA PVT1 in cancer: A review and meta-analysis. Clin Chim Acta. 2017;474:1\u20137. https:\/\/doi.org\/10.1016\/j.cca.2017.08.038.","journal-title":"Clin Chim Acta"},{"key":"849_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.omtn.2020.11.003","volume":"24","author":"X Chen","year":"2021","unstructured":"Chen X, Liu Y, Zhang Q, Liu B, Cheng Y, Zhang Y, et al. Exosomal miR-590-3p derived from cancer-associated fibroblasts confers radioresistance in colorectal cancer. Mol Therapy Nucleic Acids. 2021;24:113\u201326. https:\/\/doi.org\/10.1016\/j.omtn.2020.11.003.","journal-title":"Mol Therapy Nucleic Acids"},{"key":"849_CR22","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1038\/s41388-021-01762-0","volume":"40","author":"Y Liu","year":"2021","unstructured":"Liu Y, Tang T, Yang X, Qin P, Wang P, Zhang H, et al. Tumor-derived exosomal long noncoding RNA LINC01133, regulated by Periostin, contributes to pancreatic ductal adenocarcinoma epithelial-mesenchymal transition through the Wnt\/\u03b2-catenin pathway by silencing AXIN2. Oncogene. 2021;40:3164\u201379. https:\/\/doi.org\/10.1038\/s41388-021-01762-0.","journal-title":"Oncogene"},{"key":"849_CR23","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.3390\/cancers13184630","volume":"13","author":"Y Yi","year":"2021","unstructured":"Yi Y, Woo YM, Hwang KH, Kim HS, Lee SH. Niclosamide and Pyrvinium Are Both Potential Therapeutics for Osteosarcoma, Inhibiting Wnt\u2013Axin2\u2013Snail Cascade. Cancers. 2021;13:4630. https:\/\/doi.org\/10.3390\/cancers13184630.","journal-title":"Cancers"},{"key":"849_CR24","doi-asserted-by":"publisher","unstructured":"Walkley CR, Walia MK, Ho PW, Martin TJ. PTHrP, its receptor, and protein kinase a activation in osteosarcoma. Mol Cell Oncol. 2014;1:e965624. https:\/\/doi.org\/10.4161\/23723548.2014.965624.","DOI":"10.4161\/23723548.2014.965624"},{"key":"849_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijcard.2022.01.024","volume":"353","author":"C Tian","year":"2022","unstructured":"Tian C, Hu S, Yu J, Li W, Li P, Huang H. CREB1 transcription-activated lncRNA PVT1 promotes cardiac fibrosis via miR-145\/HCN1 axis. Int J Cardiol. 2022;353:88\u201395. https:\/\/doi.org\/10.1016\/j.ijcard.2022.01.024.","journal-title":"Int J Cardiol"},{"key":"849_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00774-025-01591-1","volume":"43","author":"Y Takeuchi","year":"2025","unstructured":"Takeuchi Y, Hagino H. Osteoanabolic agents for fracture prevention: bone building beyond bone protection. J Bone Miner Metab. 2025;43:1\u20132. https:\/\/doi.org\/10.1007\/s00774-025-01591-1.","journal-title":"J Bone Miner Metab"},{"key":"849_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.2174\/0113894501359782241216082049","volume":"26","author":"XD Yang","year":"2025","unstructured":"Yang XD, Haga CL, Phinney DG. Signaling Dynamics in Osteogenesis: Unraveling Therapeutic Targets for Bone Generation. Curr Drug Targets. 2025;26:350\u201366. https:\/\/doi.org\/10.2174\/0113894501359782241216082049.","journal-title":"Curr Drug Targets"},{"key":"849_CR28","doi-asserted-by":"publisher","unstructured":"Al-Khan AA, Al Balushi NR, Richardson SJ, Danks JA. Roles of parathyroid hormone-related protein (PTHrP) and Its receptor (PTHR1) in Normal and tumor tissues: focus on their roles in osteosarcoma. Front Veterinary Sci. 2021;8. https:\/\/doi.org\/10.3389\/fvets.2021.637614.","DOI":"10.3389\/fvets.2021.637614"},{"key":"849_CR29","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.3390\/cancers15102670","volume":"15","author":"JF Kane","year":"2023","unstructured":"Kane JF, Johnson RW. Re-Evaluating the Role of PTHrP in Breast Cancer. Cancers. 2023;15:2670. https:\/\/doi.org\/10.3390\/cancers15102670.","journal-title":"Cancers"},{"key":"849_CR30","doi-asserted-by":"publisher","unstructured":"Johnson RW, Sun Y, Ho PWM, Chan ASM, Johnson JA, Pavlos NJ, et al. Parathyroid hormone-related protein negatively regulates tumor cell dormancy genes in a PTHR1\/Cyclic AMP-independent manner. Front Endocrinol. 2018;9. https:\/\/doi.org\/10.3389\/fendo.2018.00241.","DOI":"10.3389\/fendo.2018.00241"},{"key":"849_CR31","doi-asserted-by":"publisher","first-page":"22291","DOI":"10.18632\/aging.202203","volume":"12","author":"M Chen","year":"2020","unstructured":"Chen M, Zhang R, Lu L, Du J, Chen C, Ding K, et al. LncRNA PVT1 accelerates malignant phenotypes of bladder cancer cells by modulating miR-194-5p\/BCLAF1 axis as a ceRNA. Aging. 2020;12:22291\u2013312. https:\/\/doi.org\/10.18632\/aging.202203.","journal-title":"Aging"},{"key":"849_CR32","doi-asserted-by":"publisher","unstructured":"Lv H, Zhou D, Liu G. PVT1\/miR-16\/CCND1 axis regulates gastric cancer progression. Open Med. 2023;18. https:\/\/doi.org\/10.1515\/med-2022-0550.","DOI":"10.1515\/med-2022-0550"},{"key":"849_CR33","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10689-014-9775-7","volume":"14","author":"S Li","year":"2014","unstructured":"Li S, Wang C, Liu X, Hua S, Liu X. The roles of AXIN2 in tumorigenesis and epigenetic regulation. Fam Cancer. 2014;14:325\u201331. https:\/\/doi.org\/10.1007\/s10689-014-9775-7.","journal-title":"Fam Cancer"},{"key":"849_CR34","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1128\/mcb.22.4.1172-1183.2002","volume":"22","author":"E Jho","year":"2002","unstructured":"Jho E, Zhang T, Domon C, Joo C-K, Freund J-N, Costantini F. Wnt\/\u03b2-Catenin\/Tcf Signaling Induces the Transcription of Axin2, a Negative Regulator of the Signaling Pathway. Mol Cell Biol. 2002;22:1172\u201383. https:\/\/doi.org\/10.1128\/mcb.22.4.1172-1183.2002.","journal-title":"Mol Cell Biol"},{"key":"849_CR35","doi-asserted-by":"publisher","unstructured":"Yu J, Liu D, Sun X, Yang K, Yao J, Cheng C, et al. CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt\/\u03b2-catenin signaling via transactivation of GSK-3\u03b2 and Axin2 expression. Cell Death Dis. 2019;10. https:\/\/doi.org\/10.1038\/s41419-018-1263-9.","DOI":"10.1038\/s41419-018-1263-9"},{"key":"849_CR36","doi-asserted-by":"publisher","first-page":"4488","DOI":"10.1038\/onc.2008.83","volume":"27","author":"R-C Tseng","year":"2008","unstructured":"Tseng R-C, Lin R-K, Wen C-K, Tseng C, Hsu H-S, Hsu W-H, et al. Epigenetic silencing of AXIN2\/betaTrCP and deregulation of p53-mediated control lead to wild-type \u03b2-catenin nuclear accumulation in lung tumorigenesis. Oncogene. 2008;27:4488\u201396. https:\/\/doi.org\/10.1038\/onc.2008.83.","journal-title":"Oncogene"},{"key":"849_CR37","doi-asserted-by":"publisher","unstructured":"Wu Z-Q, Brabletz T, Fearon E, Willis AL, Hu CY, Li X-Y et al. Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity. Proceedings of the National Academy of Sciences. 2012;109:11312\u20137. https:\/\/doi.org\/10.1073\/pnas.1203015109.","DOI":"10.1073\/pnas.1203015109"},{"key":"849_CR38","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nrendo.2015.139","volume":"11","author":"RW Cheloha","year":"2015","unstructured":"Cheloha RW, Gellman SH, Vilardaga J-P, Gardella TJ. PTH receptor-1 signalling\u2014mechanistic insights and therapeutic prospects. Nat Reviews Endocrinol. 2015;11:712\u201324. https:\/\/doi.org\/10.1038\/nrendo.2015.139.","journal-title":"Nat Reviews Endocrinol"},{"key":"849_CR39","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1161\/circresaha.124.324762","volume":"135","author":"M Zhao","year":"2024","unstructured":"Zhao M, Cao N, Gu H, Xu J, Xu W, Zhang D, et al. AMPK Attenuation of \u03b2-Adrenergic Receptor-Induced Cardiac Injury via Phosphorylation of \u03b2-Arrestin-1-ser330. Circul Res. 2024;135:651\u201367. https:\/\/doi.org\/10.1161\/circresaha.124.324762.","journal-title":"Circul Res"},{"key":"849_CR40","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.7314\/apjcp.2014.15.2.1041","volume":"15","author":"J-X Wu","year":"2014","unstructured":"Wu J-X, Shan F-X, Zheng J-N, Pei D-S. \u03b2-arrestin Promotes c-Jun N-terminal Kinase Mediated Apoptosis via a GABABR\u00b7\u03b2-arrestin\u00b7JNK Signaling Module. Asian Pac J Cancer Prev. 2014;15:1041\u20136. https:\/\/doi.org\/10.7314\/apjcp.2014.15.2.1041.","journal-title":"Asian Pac J Cancer Prev"},{"key":"849_CR41","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2017.3288","author":"Q Song","year":"2017","unstructured":"Song Q, Ji Q, Li Q. The role and mechanism of \u03b2\u2013arrestins in cancer invasion and metastasis (Review). Int J Mol Med. 2017. https:\/\/doi.org\/10.3892\/ijmm.2017.3288.","journal-title":"Int J Mol Med"},{"key":"849_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00114","author":"A Bagnato","year":"2019","unstructured":"Bagnato A, Rosan\u00f2 L. New Routes in GPCR\/\u03b2-Arrestin-Driven Signaling in Cancer Progression and Metastasis. Front Pharmacol. 2019;10. https:\/\/doi.org\/10.3389\/fphar.2019.00114.","journal-title":"Front Pharmacol"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-026-00849-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00849-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00849-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:05:16Z","timestamp":1789988716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13062-026-00849-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["849"],"URL":"https:\/\/doi.org\/10.1186\/s13062-026-00849-6","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Clinical Ethics Committee of Liaoning Cancer Hospital & Inst (Approval No. 202205K9). All animal experiments were approved by the Animal Ethics Committee of Liaoning Cancer Hospital & Inst (Approval No. CMUKT2025160) and were conducted in strict accordance with the guidelines of the National Institutes of Health (NIH) for the Care and Use of Laboratory Animals, as well as the ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"181"}}